Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib 60 mg versus 140 mg in advanced metastatic medullary thyroid cancer
MOH_2017-06-18_000530Phase 4Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cabozantinib in Medullary Thyroid Cancer (MTC) (2 arms), sponsored by Exelixis, Inc. Primary endpoint: Efficacy comparison of cabozantinib 60 mg/day versus 140 mg/day. Started Dec 2014; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on MOH_2017-06-18_000530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-18_000530.